Shenghong Ma
is currently focusing on the mechanisms of Hippo pathway regulation.
Education
| 2006-2010 | B.S. Biological Science, Zhejiang University, China |
|---|---|
| 2010-2015 | Ph.D. Biochemistry and Molecular Biology, Fudan University, China |
| 2016-present | Postdoctoral fellow in the Department of Pharmacology, UC San Diego, CA |
|---|
Selected Publications
L2hgdh deficiency accumulates L-2-hydroxyglutarate with progressive leukoencephalopathy and neurodegeneration.
Ma S, Sun R, Jiang B, Gao J, Deng W, Liu P, he R, Cui J, Ji M, Yi W, Yang P, Wu X, Xiong Y, Qiu Z, Ye D, Guan KL.
Mol Cell Biol. (2017). in pressOncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
Wang P, Wu J, Ma S, Zhang L, YAo J, Hoadley KA, Wilderson MD, Perou CM, Guan KL, Ye D, Xiong Y.
Cell Rep. (2015). 13:2353-2361D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth.
Ma S, Jiang B, Deng W, Gu ZK, Wu FZ, Li T, Xia Y, Yang H, Ye D, Xiong Y, Guan KL.
Oncotarget. (2015). 6:8606-8620R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis.
Ye D, Ma S, Xiong Y, Guan KL.
Cancer Cell. (2013). 23:274-276